A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes by Schäfer, Daniel et al.
ORIGINAL RESEARCH
published: 07 August 2020
doi: 10.3389/fimmu.2020.01704

















†These authors share first authorship
‡These authors share last authorship
Specialty section:
This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Immunology
Received: 03 March 2020
Accepted: 25 June 2020
Published: 07 August 2020
Citation:
Schäfer D, Henze J, Pfeifer R,
Schleicher A, Brauner J,
Mockel-Tenbrinck N, Barth C,
Gudert D, Al Rawashdeh W,
Johnston ICD and Hardt O (2020) A
Novel Siglec-4 Derived Spacer
Improves the Functionality of CAR T
Cells Against Membrane-Proximal
Epitopes. Front. Immunol. 11:1704.
doi: 10.3389/fimmu.2020.01704
A Novel Siglec-4 Derived Spacer
Improves the Functionality of CAR T
Cells Against Membrane-Proximal
Epitopes
Daniel Schäfer 1,2†, Janina Henze 1,2†, Rita Pfeifer 2†, Anna Schleicher 3, Janina Brauner 2,
Nadine Mockel-Tenbrinck 2, Carola Barth 2, Daniela Gudert 2, Wa’el Al Rawashdeh 2*‡,
Ian C. D. Johnston 2*‡ and Olaf Hardt 2*‡
1 Translational Molecular Imaging, Institute for Diagnostic and Interventional Radiology & Clinic for Hematology and Medical
Oncology, University Medical Center Göttingen, Göttingen, Germany, 2 R&D Reagents, Miltenyi Biotec B.V. & Co. KG,
Bergisch Gladbach, Germany, 3 Faculty of Chemistry and Biosciences, Karlsruher Institute of Technology, Karlsruhe, Germany
A domain that is often neglected in the assessment of chimeric antigen receptor (CAR)
functionality is the extracellular spacer module. However, several studies have elucidated
that membrane proximal epitopes are best targeted through CARs comprising long
spacers, while short spacer CARs exhibit highest activity on distal epitopes. This finding
can be explained by the requirement to have an optimal distance between the effector T
cell and target cell. Commonly used long spacer domains are the CH2-CH3 domains of
IgG molecules. However, CARs containing these spacers generally show inferior in vivo
efficacy in mouse models compared to their observed in vitro activity, which is linked
to unspecific Fcγ-Receptor binding and can be abolished by mutating the respective
regions. Here, we first assessed a CAR therapy targeting membrane proximal CD20
using such amodified long IgG1 spacer. However, despite thesemutations, this construct
failed to unfold its observed in vitro cytotoxic potential in an in vivomodel, while a shorter
but less structured CD8α spacer CAR showed complete tumor clearance. Given the
shortage of well-described long spacer domains with a favorable functionality profile, we
designed a novel class of CAR spacers with similar attributes to IgG spacers but without
unspecific off-target binding, derived from the Sialic acid-binding immunoglobulin-type
lectins (Siglecs). Of five constructs tested, a Siglec-4 derived spacer showed highest
cytotoxic potential and similar performance to a CD8α spacer in a CD20 specific CAR
setting. In a pancreatic ductal adenocarcinomamodel, a Siglec-4 spacer CAR targeting a
membrane proximal (TSPAN8) epitope was efficiently engaged in vitro, while a membrane
distal (CD66c) epitope did not activate the T cell. Transfer of the TSPAN8 specific Siglec-4
spacer CAR to an in vivo setting maintained the excellent tumor killing characteristics
being indistinguishable from a TSPAN8 CD8α spacer CAR while outperforming an IgG4
long spacer CAR and, at the same time, showing an advantageous central memory
CAR T cell phenotype with lower release of inflammatory cytokines. In summary, we
developed a novel spacer that combines cytotoxic potential with an advantageous T
cell and cytokine release phenotype, which make this an interesting candidate for future
clinical applications.
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INTRODUCTION
The unprecedented therapeutic efficacy of CAR T cells in
previously refractory blood cancers is considered to be one of
the major breakthroughs in cancer immunotherapy, culminating
in the recent market approvals by the Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) for two CAR T cell products (1–7). While CAR therapies
have now achieved public recognition, their development and
the quest for optimal CAR design has been a multistep process
stretching over several decades. Ever since their initial description
in 1989 by Eshhar et al. (8), the receptors have evolved from a
two-chimeric-TCR chain architecture to a one-protein design.
This design commonly incorporates a single-chain variable
fragment (scFv) of a given antibody as the antigen binding
moiety, an extracellular spacer and a transmembrane region as
structural features, as well as signal transduction units for T cell
activation. Originally, the spacer domain was introduced into the
CAR framework as an inert building block to allow the antigen
binding moiety to extend beyond the T cell’s glycocalyx and
improve antigen accessibility (9). Following this assumption, a
plethora of spacer regions were designed simultaneously ranging
from the immunoglobulin (Ig) domains of the crystallizable
fragments (Fc) of antibodies to extracellular domains of CD8α,
CD28, the TCRβ chain or NKG2D (10–16) and were applied
without comparative analyses. However, already very early on,
Patel and colleagues provided the scientific proof that the spacer
region can be of paramount importance for the receptor function
and affects its expression, surface stability through the turnover
rate, and signal transduction (17). More recent accumulating
research has further been showing that in addition to the
nature of the spacer, effective antigen recognition depends on
the functional interplay between the spatial localization of the
target epitope and the CAR spacer length (18–20). For instance,
membrane-distal epitopes were shown to most efficiently trigger
CARs with short spacers, while membrane-proximal epitopes
required receptors with extended spacer domains to elicit
accurate effector function, in this way emphasizing the biological
requirement of optimal T cell-target cell distance (18–22). Thus,
the design of CARs against novel antigens needs to consider
both the epitope position within the target antigen as well as
the nature and length of the spacer region and customize these
variables accordingly.
The use of Ig-derived spacers is particularly attractive as it
provides the opportunity to modulate the spacer length into
long (CH2-CH3 domain), medium (CH3) and short (hinge only)
structures, while retaining the nature of the parent protein.
However, Ig-derived spacers have faced various complications
during their development. In particular, off-target activation,
CAR T cell sequestration in the lung, tonic signaling and
activation-induced cell death (AICD) have been described
leading to only a limited T cell persistence (23–26). Although
these effects could be abrogated by mutating the amino acid
sequence essential for FcR binding (23, 25, 27), it needs to be
taken into consideration that these experiments were conducted
in immunosuppressed NSG mice and whether FcR binding can
be entirely eliminated in humans remains unclear. Of note,
several clinical studies that used IgG-derived spacers described
only limited anti-tumor efficacy and low CAR T cell persistence
(28–31) while others are showing some promising clinical
responses (32–34). Interestingly, the first commercially available
CAR T cell-based therapies use CD28 (Yescarta) and CD8
(Kymriah) derived spacer domains.
Taking into account the shortage of well-described long spacer
domains with a favorable functionality profile, we endeavored to
develop a novel long spacer for membrane-proximal epitopes,
which naturally lacks an FcR binding domain. Based on the
postulated spatial requirements between CARs and their target
antigens, we anticipated finding a CAR spacer construct whose
functionality against membrane-proximal epitopes extends
beyond that of a CD8α spacer CAR. Hence, we generated
novel CAR spacers and analyzed their efficacy side-by-side to
the cognate CD8α spacer counterpart – a comparison that has
not been extensively undertaken thus far. The design of the
novel spacers was based on the sialic acid binding Ig-like lectin
(Siglec) receptor family, whose members are broadly expressed
on various immune cells (35, 36). Structurally, each receptor
member is composed of an N-terminal Ig-like V-set domain
which is involved in sialic acid binding and a defined number
of Ig-like C2-set domains that serve as a structural spacer and
extend the binding moiety away from the plasma membrane.
The selection of the Siglec family was inspired by the hypothesis
that the incorporation of naturally occurring spacer domains into
the CAR architecture will preserve the biological requirements
of a spacer region and minimize unspecific interactions with
other cells.
In this study, we confirm this strategy of using naturally
occurring spacer domains by first demonstrating, that in a
CD20+ lymphoma model a long IgG1 spacer CAR is as
functional as the CD8α spacer in vitro, but fails to translate
its effectiveness in vivo, despite containing the earlier reported
mutations to abrogate FcR binding (23). Subsequently, we
evaluate novel spacers derived from the Siglec family of proteins
and identify a long alternative spacer derived from Siglec-4 that
performs with equal efficiency to the CD8α spacer in vitro.
Finally, we demonstrate in a solid tumor model that the novel
Siglec-4 spacer CAR does not exceed, but rather matches the
CD8α spacer CAR cytotoxic activity in vivo on membrane-
proximal targets, while maintaining a favorable cell phenotype
profile and cytokine release pattern.
MATERIALS AND METHODS
CAR Gene Construction
Commercial gene synthesis in combination with an optimization
algorithm for codon usage in humans (ATUM) was used to
construct the CAR genes of interest. The CD20-specific scFv
was derived from the murine monoclonal antibody Leu16 as
originally described by Jensen and colleagues (37), while the
CD66c- and TSPAN8-targeting scFv sequences were derived
from the antibody clones REA414 (CD66c) and REA443
(TSPAN8) (Miltenyi Biotec). All antigen binding domains
contained a (G4S)3-linker between the VL and the VH regions. To
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facilitate receptor trafficking to the plasma membrane, a human
CD8α leader signaling peptide was added N-terminally to the
respective scFv sequence. The spacer region downstream of the
scFv encompassed either the domain for IgG1 hinge-CH2CH3
(234 amino acids), IgG4 hinge-CH2CH3 (228 amino acids), or
CD8α hinge (45 amino acids). To abrogate potential interactions
of the Fc spacer CARs with FcR-expressing cells, the PELLGG
and ISR motives in the IgG1 CH2 domain were replaced by the
corresponding IgG2 amino acids (23). In the case of the IgG4
CH2 domain, the APEFLG sequence was replaced by APPVA
from IgG2 and an N279Q mutation was introduced to remove
glycosylation at this site (25). Spacers derived from the Siglec
family were designed based on the protein sequences extracted
from UniProt and the plasma membrane-proximal domains
were incorporated into the CAR architecture. Thus, the Siglec-3
spacer comprised the amino acids 145–259 of the parent protein
with a C169S mutation to abrogate unspecific disulfide-bond
formation. The Siglec-4 spacer contained the amino acids 238–
519, the Siglec-7.1 spacer the amino acids 150–353, the Siglec-
7.2 spacer the amino acids 234–353, and the Siglec-8 spacer the
amino acids 241–363 of the respective parent protein. All spacers
were linked to the transmembrane domain of human CD8α, the
intracellular domain of 4-1BB, and the CD3ζ signaling domain as
derived from UniProt. The CAR genes were fused to a Furin-P2A
sequence to include co-expression of the truncated low affinity
nerve growth factor receptor (1LNGFR). Transgene expression
was promoted by the PGK promoter located upstream of the
CAR gene.
Lentiviral Vector Production
Second generation self-inactivating VSV-G-pseudotyped
lentiviral vectors were produced by transient transfection of
adherent HEK293T cells. One day before transfection, 1.6 × 107
HEK293T cells were seeded per T175 flask to reach a confluency
of 70–90% on the following day. Each T175 flask was then
transfected with a total of 35 µg plasmid DNA composed of
pMDG2 (encoding VSV-G), pCMVdR8.74 (encoding gag/pol),
and the respective transgene-encoding transfer vector using
MACSfectin reagent (Miltenyi Biotec). All transfection reactions
were performed with a DNA: MACSfectin ratio of 1:2. Following
overnight incubation, sodium butyrate was supplied at a final
concentration of 10mM and at 48 h after transfection the
medium was collected, cleared by centrifugation at 300 × g
and 4◦C for 5min and filtered through 0.45 µm-pore-size
PVDF filters. Concentration of the viral stock was performed by
centrifugation at 4◦C and 4,000 × g for 24 h. Pellets containing
lentiviral vector were air-dried and resuspended at a 100-fold
concentration with 4◦C cold PBS. Lentiviral vector aliquots were
stored at−80◦C.
Generation of CAR T Cells
Automated CAR T Cell Generation
The CliniMACS Prodigy R© TCT (T cell transduction) application
was used for the automated manufacturing of large amounts
of gene-modified T cells. Technical features and experimental
procedures have previously been described in detail (38, 39). In
brief, T cells were obtained from non-mobilized leukapheresis
from healthy anonymous donors (University Hospital Cologne
or the German Red Cross Ulm) and were typically processed
24–48 h after collection. Transduced and enriched CAR T
cells were finally formulated and harvested in Composol R©
solution (Fresenius Kabi), supplemented with 2.5% human
serum albumin (Grifols). For quality assurance, the transduction
efficiency and T cell phenotype was determined using a
MACSQuant Analyzer 10 (Miltenyi Biotec) after the TCT
process. Transduction efficiency were determined by flow
cytometry on days 5 and 12 of the TCT process using a
flow cytometer.
Manual CAR T Cell Generation
Buffy coats from healthy anonymous donors were obtained
from the German Red Cross Dortmund. Peripheral blood
mononuclear cells (PBMCs) were then isolated from buffy coats
by density gradient centrifugation. T cells were purified from
PBMCs applying the Pan T Cell Isolation Kit, human (Miltenyi
Biotec) and activated in TexMACSTM Medium (Miltenyi Biotec)
supplemented with T Cell TransActTM, human (Miltenyi Biotec)
and 100 IU/ml of recombinant Human IL-2 IS, research grade
(Miltenyi Biotec). T cells were transduced 24 h after activation
using VSV-G pseudotyped lentiviral particles. 3 days post
activation, T Cell TransActTM, human and excess viral vector
were removed and T cells were cultured in TexMACSTM Medium
only supplemented with IL-2. T cells were expanded for 12 days
and used directly for in vitro assays or frozen in TexMACSTM
Medium containing 10% DMSO for later in vivo use. Frozen T
cells that were used for in vivo testing were thawed 24 h before
injection and cultivated at 37◦C in TexMACSTM Mediumwithout
further supplements.
Target Cell Lines
HEK293T, JeKo-1, Raji and AsPC1 cells were obtained from
ATCC and cultured as recommended. Raji cells were transduced
with with a ffLuc cassette for in vivo detection and AsPC1 cells
were transduced with with a eGFP/ffLuc cassette for in vitro
and in vivo detection. To validate authenticity of the cell lines
used, we used the Human STR Profiling Cell Authentication
Service (ATCC).
Flow Cytometry
Antibodies specific for anti-human CD62L, CD45RO, CD95,
CD271 (LNGFR), CD107a, TNF-α, CD223 (LAG3), CD279
(PD1), CD366 (TIM3), CD137 (4-1BB), CD4, CD8, CD3
were monoclonal recombinant antibodies (Miltenyi Biotec). For
anti-CD20 CAR detection the CD20 CAR Detection Reagent
(Miltenyi Biotec) was used. Staining ofMiltenyi Biotec antibodies
was performed according to the supplier’s instructions. For
direct CAR detection of CD66c and TSPAN8 specific CARs
a sequential staining was used. First, samples were incubated
with polyclonal Fab specific anti-mouse IgG antibodies produced
in goat (Merck) at concentrations of 10µg/ml for 30min at
4◦C. Samples were washed and then incubated with polyclonal
anti-goat IgG antibodies produced in chicken (Thermo Fisher)
at concentrations of 10µg/ml for 30min at 4◦C. Stained
samples were measured on a MACSQuant R© Analyzer 8 or
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MACSQuant Analyzer 10 (Miltenyi Biotec) and analyzed using
the MACSQuantifyTM Software.
In vitro Functional Assays
With JeKo-1 Target Cells
1 × 105 JeKo-1 and 1 × 105 CAR T cells were co-cultured in
TexMACSTM Medium (Miltenyi Biotec) for 24 h in 96-well round
bottom plates. Supernatants were collected at the endpoint and
used to detect the cytokines released by anti-CD20 CAR T cells
using the MACSPlex Cytokine 12 Kit (Miltenyi Biotec) with the
four selected human cytokines IFN-γ, IL-2, TNF-α and GM-
CSF, according to the manufacturer’s instructions. The cytolytic
activity of the engineered T cells was evaluated by using 1 × 104
CD20+ JeKo-1 cells labeled with 1µM CellTraceTM Violet (Life
Technologies), as target cells. Effector and target cells were co-
cultured for 24 h at the indicated ratios (E:T) in 96-well round
bottom plates. Detection of the specific lysis was performed by
quantitation of Violet dye labeled target cells using aMACSQuant
Analyzer 8 (Miltenyi Biotec). Mock-transduced T cells were used
as control at the same effector-to-target ratios.
With Raji Cells
2 × 105 CAR T cells were incubated with 2 × 105 CD20+ Raji
cells in 200 µl TexMACSTM Medium at 37◦C. In addition, the
medium was supplemented with 20 µl of a CD107a specific
antibody. After 1 h of incubation the protein transport inhibitors
Monensin and Brefeldin A (BD Biosiences) were added as
recommended for 4 h. After this incubation period, cells were
washed and first surface stained with LNGFR specific antibodies
to label transduced T cells and subsequently intracellularly
stained for TNF-α using the Inside Stain Kit and a TNF-α specific
antibody (all Miltenyi Biotec). Cells were then measured by flow
cytometry. For TIM3, LAG3 and PD1 detection 1 × 105 CAR T
cells were inoculated with 2 × 105 CD20+ Raji cells in 200 µl
TexMACSTM Medium at 37◦C for 24 h. Subsequently T cells were
stained and analyzed by flow cytometry.
For functionality assays in the presence of NSG macrophages,
2 × 105 CAR T cells were incubated in a 1:1:1 ratio with Raji
target cells and macrophages derived from a peritoneal lavage.
The assay was performed in the presence or absence of murine
FcR-blocking reagent. After 24 h of incubation, detection of the
specific lysis was performed by quantitation of Violet dye labeled
target cells via flow cytometry using a MACSQuant Analyzer 8
(Miltenyi Biotec).
With AsPC1 Cells
GFP+/Luc+ AsPC1 target cells were inoculated in 96-well plates
at 2.5 × 104 cells per well in TexMACSTM Medium. CAR T cells
or untransduced Mock T cells were added with at an E:T ratio of
2:1. The amount of T cells in theMock control was adjusted to the
number of total T cells in the CAR group with the highest total
cell count. Cytotoxicity wasmeasurement as the decrease of green
surface area as assessed by the IncuCyte R© S3 Live-Cell Analysis
System (Sartorius). Measured values were normalized to the start
of the experiment. After 24 h a supernatant sample was taken for
cytokine measurements using the MACSPlex Cytokine 12 Kit.
At the end of the experiment expression of LAG3, PD1, and 4-
1BB were measured using a MACSQuant Analyzer 8 (Miltenyi
Biotec). Specific endpoint killing was calculated from the green
surface area values with the following formula:








Experiments involving animal handling were approved by the
Governmental Review Committee on Animal Care in NRW,
Germany and performed according to guidelines and regulations
(Landesamt für Natur, Umwelt and Verbraucherschutz NRW,
Approval number 84-02.04.2015.A168 and Approval number
84-02.04.2017.A021).
Raji lymphoma were established by tail vein injection of 5
× 105 Raji Luc+ cells. After 7 days, 1 × 106 CAR T cells or
Mock GFP-transduced T cells, adjusted to the total amount of
T cells according to transduction efficiency of the CARs, were
infused intravenously.
For AsPC1 GFP+/Luc+ cell line derived tumors 1 × 106
cells were injected subcutaneously in the right flank of NOD
SCID gamma (NSG; NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice
(Jackson Laboratory, provided by Charles River). When tumors
reached a size of 25 mm², 5× 106 CAR T cells were injected into
the tail vein. The amount of injected untransduced Mock T cells
was adjusted to the number of total T cells in the CAR group with
the highest total cell count.
Therapeutic response was measured longitudinally using
the IVIS Lumina in vivo imaging system (PerkinElmer)
after intraperitoneal injection of 100 µL (30 mg/mL) D-
Luciferin (for Raji studies: XenoLight Rediject D-Luciferin Ultra
(PerkinElmer). For AsPc1 studies: Potassium Salt, LUCK-2G,
GoldBio) and additionally by manual caliper measurement for
pancreatic tumors. All measures to secure the well-being of mice
were executed following the relevant animal use guidelines and
ethical regulations. Upon reaching the endpoint (weight loss
of >19%, paralysis, stress score of >20 or end-point of the
experiment, Day 20 for the lymphoma model and Day 29 for
the pancreatic model), animals were euthanized according to
guidelines and post-mortem analysis was performed in order to
determine tumor burden, persistence and killing of the different
CAR T cell constructs. In particular blood, bone marrow and
spleen were subjected to flow cytometric analysis. Therefore,
spleen was dissociated using the gentleMACSTM Octo Dissociator
with Heaters according to the manufacturers protocol (Miltenyi
Biotec) and bone marrow was extracted from the femurs and
tibias of mice by cutting off the epiphyses of the bones and
rinsing the inner fragments. The cell suspensions were filtered
through a 70µm pore size MACS SmartStrainer (Miltenyi
Biotec) and following red blood cell lysis on blood, bone marrow
and spleen single cell suspensions using Red Blood Cell Lysis
Solution (Miltenyi Biotec), samples were stained and analysis was
conducted on a MACSQuant Analyzer 8.
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FIGURE 1 | CD20 specific CAR T cells with short CD8α and long IgG1 CH2-CH3 spacers show similar in vitro functionality. (A) Structure of the three CD20 CAR
constructs. (B) T cell phenotypes in the CD4/CD8 enriched fraction on d0, d5, and d12 of the automated T cell transduction process by flow cytometry. (C) GM-CSF,
IFN-γ, IL-2, IL-6, and TNF-α production after 24 h co-culture of CD20 CAR T cells with CD20+ JeKo-1 target cells at 1:1 effector to target ratio analyzed by flow
cytometry. n = 3. (D) Cytolytic activity of the engineered CAR T cells. Effector CAR T cells and target-positive JeKo-1 target cells were co-cultured for 24 h at the
indicated ratios (E:T). Detection of the specific lysis was performed by flow cytometry. n = 3.
Statistics
Unless otherwise specified, all graphical error bars represent
standard error of the mean. Statistical comparisons between
more than two groups were conducted by One-way ANOVAwith
p < 0.05 using GraphPad Prism 7. To facilitate the statistical
overview of the in vivo experiments, the significance analyses
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were organized in a pairwise significance matrix (PSM) where
each box represents a comparison between two groups, as shown
by Al Rawashdeh et al. (40). The order, in which the groups were
compared, is illustrated in Figures S1, S4. Significant differences
between two comparing groups are defined by a green box, while
insignificant differences by a red box.
RESULTS
CD20 Specific CD8α and IgG1 CH2-CH3
Spacer CARs Exhibit Comparable in vitro
Activity
During pre-clinical development of a CD20 directed CAR
candidate (39) we also evaluated a number of different CAR
configurations (Figure 1A). We used an scFv derived from
the Leu16 monoclonal antibody (30, 41), binding to the large
extracellular loop of CD20 (42). This loop is only 47 amino acids
long, which is why we hypothesized it would be more effectively
targeted with a flexible CD8α or long IgG spacer. We generated
two second generation CAR constructs, that comprised a CD8α
transmembrane domain, a 4-1BB co-stimulatory domain and a
CD3ζ main activator domain. Both bind CD20 via the Leu16
derived scFv in a VH-VL orientation and only differed in the
spacer domain. The CD20_hl_IgG1 CAR comprises an IgG1
CH2-CH3 spacer while the CD20_hl_CD8 CAR possesses a
CD8α spacer. The PELLGG and ISR motif of the IgG1 CH2-
CH3 spacer were replaced by the corresponding IgG2 amino
acids to reduce Fcγ-Receptor binding, as described previously
(23). To assess whether the order of binding domains in the scFv
also can play a role in CAR function, we constructed a CD8α
spacer CAR with swapped scFv orientation (CD20_lh_CD8). We
generated CD20 specific CAR T cells by genetically modifying
CD3/CD28 polyclonally activated T cells with lentiviral vectors
in a fully automated manner in a closed system using the
CliniMACS Prodigy R© as described previously (39). At the end
of the manufacturing on day 12, similar T cell phenotypes
were obtained for the samples modified with the different CAR
constructs and the untransduced Mock control (Figure 1B).
More than 80% of T cells had a memory phenotype (central
memory T cell (TCM) and stem cell memory T cell (TSCM) as
defined by their phenotypes being CD62L+/CD45RO+/CD95+
and CD62L+/CD45RO−/CD95+, respectively). Also, the three
constructs demonstrated comparable functionality in terms of
cytokine release (Figure 1C) and cytotoxicity (Figure 1D) upon
co-culture with CD20+ JeKo-1 target cells.
CD8α and IgG1 CH2-CH3 Spacer CARs
Differ in Their in vivo Performance
Having assessed the in vitro activity, we next analyzed the
same lentivirally modified T cells in a pre-clinical NSG mouse
model. 5 × 105 CD20+ Raji cells, which were modified to
constitutively express luciferase, were injected into the tail vein of
each mouse. Seven days later, 1 × 106 CD20 specific CAR T cells
or GFP transduced Mock T cells (Figure 2A) were also applied
intravenously. Tumor burden was monitored longitudinally
over 3 weeks by non-invasive bioluminescent imaging (BLI)
of tumor cells in vivo. Neither the Mock treated group nor
mice treated with the IgG1 spacer CAR showed any control of
tumor growth compared to the untreated group, and the animals
in these groups were sacrificed according to the ethical code
on day 17 and day 15, respectively (Figure 2B). On the other
hand, significant therapeutic responses were achieved by the
CD20_hl_CD8 and CD20_lh_CD8 CAR T cells (Figures 2B,D).
Both groups exhibited a reduced tumor growth 6 days post T
cell injection. While the CD20_hl_CD8 CAR T cells reached
background fluorescence on day 13, CAR T cells equipped with
the same CAR but with the scFv in the converse orientation
needed longer to reduce tumor burden and did not reach
background levels until the end of the experiment. This difference
between the scFv variants could be attributed to a single mouse
having remnants of tumor present in the jawbone, which in our
experience is difficult to treat and possibly inaccessible to CAR
T cells. We verified that the scFv orientation indeed had only
a minor influence by repeating the experiment with the CD8α
spacer CARs with the different scFv orientations using a different
donor (Figures 2C,E). Again, both groups of CAR-modified T
cells were effective in rapidly controlling the tumor growth, with
no significant difference being observed between the different
scFv orientations. Ex vivo analysis of spleen, bone marrow and
blood at the end of the study showed no detectable IgG1 spacer
CAR T cells in the treated mice while CAR T cells with the
CD8α spacer could be readily detected, implying a reduced in
vivo persistence or expansion of the T cells modified with the
IgG1 spacer CAR (Figure S2).
These findings were in line with earlier results of other groups,
showing reduced in vivo efficacy of full length IgG family spacers
(25, 27). These groups mutated FcR binding sites or developed
other solutions in order to decrease off-target binding of the T
cell, which we were also able to confirm in an in vitro assay
using mouse macrophages (Figure S3), but it is unclear whether
all potential off-target binding has been abrogated as binding to
other lower affinity FcγRs may be retained (25).
Construction and Characterization of a
New Family of CAR Spacers
These findings motivated us to develop a new class of CAR
spacer regions that naturally lack FcR binding sites. In this
context we identified the Sialic acid-binding immunoglobulin-
type lectin (Siglec) family whose members are expressed on
various immune cells and incorporate Ig-like domains in their
receptor architecture (43, 44). More specifically, while the
membrane distal sialic acid binding Ig-like V-set domain is
positioned N-terminally, the more C-terminally located Ig-like
C2-set domains, which vary in number, serve as spacer regions.
Based on previous reports describing that CAR T cell activation
can be optimized according to the epitope location and spacer
length, we selected one, two or three C2-set domains derived
from Siglec-3, -4, -7, or -8 for spacer design (Figure 3).
To confirm correct translation and surface expression of
the constructs, bicistronic lentiviral expression vectors were
generated with a downstream 1LNGFR gene linked to the CAR
by a P2A sequence (Figure 4A). After transfection of the DNA
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FIGURE 2 | CD20 specific CAR T cells with an IgG1 spacer domain fail to exhibit in vivo efficacy. (A) Overview of the study workflows. (B) Tumor burden change over
time in mice treated with anti-CD20 IgG1 CH2-CH3 and CD8α spacer CAR T cells from one donor. n = 5/group. PSM p < 0.05 (green) [one-way ANOVA]. (C) Tumor
burden change over time in presence of the two different CD8α CAR constructs with T cells from a second donor. n = 6/group. PSM p < 0.05 (green) [one-way
ANOVA]. (D) Representative in vivo bioluminescence images of tumor bearing mice from (B). Images are arranged according to the treatment group and time after
CAR T cell injection. T cells were generated from one donor. Scale factor: min: 5 × 106, max: 5 × 108 p/s. (E) Representative in vivo bioluminescence images of
tumor bearing mice from (C). Images are arranged according to the treatment group and time after CAR T cell injection. T cells were generated from a second donor.
Scale factor: min: 5 × 106, max: 5 × 108 p/s.
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FIGURE 3 | Overview of Siglec membrane proteins used for CAR construction.
constructs into HEK293T cells, detection of the reporter protein
1LNGFR confirmed successful transcription and translation of
the CAR cassette, while direct staining of the CAR with a
CD20 CAR detection reagent (PE) visualized surface expression
of the CAR constructs. All constructs showed both 1LNGFR
and CAR expression in >80% of HEK293T cells (Figure 4B).
Subsequently, we transduced primary T cells with lentiviral
vectors and assessed the CAR expression 6 days post transduction
(Figure 4C). The 1LNGFR reporter protein was expressed in
all cases demonstrating effective lentiviral transduction of the
T cells and translation of the expression cassette (range 46–
75% LNGFR+ T cells). However, while three CAR constructs
showed CAR expression levels comparable to the CD8α spacer
CAR control, no CD20_hl_Sig7.1 CAR expression was detectable
and the CD20_hl_Sig3 CAR was expressed on only 5% of the T
cells. Based on these results, we excluded these constructs from
further analysis.
Siglec-4 Spacer Shows Comparable
in vitro Functionality To CD8α Spacer in a
CD20 CAR Model
Next, we investigated the cytotoxic potential of the novel
constructs. We co-cultured CAR T cells for 5 h with CD20+
Raji cells or CD20− HEK293T cells at an E:T ratio of 1:1.
Effector function was assessed by determining degranulation
and intracellular detection of the cytokine TNF-α in the
transduced cells (gated on 1LNGFR expression). Only CAR
T cells co-cultured with CD20+ target cells showed significant
degranulation (Figure 4D). Strongest degranulation could be
observed for the CD8α and Siglec-4 spacer variants with around
35% of CD107α positive cells. The Siglec-7.2 spacer CAR
produced an intermediate amount of CD107α at 20% positive
cells and the Siglec-8 variant had the lowest degranulation
with only 10% positive cells but still more than the negative
controls (Figure 4D). Similar to the degranulation analysis, the
proportion of1LNGFR+/TNF-α+ cells was also highest in CD8α
spacer CART cells (Figure 4E; 31%) but the CD20_hl_Sig4 CARs
only displayed 18% of TNF-α positive cells, followed by Siglec-7.2
and Siglec-8 spacer CARs. Again, no unspecific activation could
be observed in the controls.
We also assessed the activation state of the modified T cells
by analyzing TIM3, LAG3, and PD1 surface expression. CD20+
Raji cells were co-cultured with CAR T cells for 24 h at an E:T
ratio of 1:2. The CD8α and Siglec-4 spacer CAR modified T
cells contained the largest fraction of TIM3/LAG3/PD1 triple
positive cells (Figure 4F). As the Siglec-7.2 and Siglec-8 spacer
CAR T cells displayed lower degranulation and upregulation of
activation markers after antigen engagement throughout these
in vitro experiments, we decided to investigate only the Siglec-4
spacer in more detail.
The Siglec-4 Spacer CAR Displays High
Functional Potency Against
Membrane-Proximal Targets
In our CD20+ Raji lymphoma model the Siglec-4 spacer CAR
demonstrated a comparable in vitro functionality to the CD8α
spacer CAR. As described above the Leu16 epitope is very
proximal to the target cell membrane, making it more susceptible
for engagement with long spacer CARs. From the CAR variants
that could be efficiently expressed in T cells, the Siglec-4 spacer
was the only spacer with three C2-set Ig domains, agreeing with
previous work that long spacers are excellent for targeting “short,”
membrane-proximal targets. To verify this hypothesis and to
prove the robustness of the Siglec-4 spacer functionality, we
assessed the Siglec-4 spacer CAR in an additional solid tumor
model of pancreatic ductal adenocarcinoma (PDAC). We have
recently identified CD66c and TSPAN8 as novel target candidates
for cellular treatment of PDAC (Schäfer et al. manuscript under
revision). These two target molecules are especially suitable for
investigating our novel long spacer, as the scFv binding epitopes
differ greatly in terms of membrane proximity.
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FIGURE 4 | In vitro evaluation of novel CD20 specific Siglec spacer CAR T cells. (A) Modular structure of the CD20 CAR constructs with the Siglec spacers and
extracellular domain comparison of the CAR constructs. (B) Expression analysis of the CAR constructs in transiently transfected HEK293T cells 24 h post transfection
and (C) in transduced T cells from two donors 6 days post transduction. LNGFR and CAR expression were evaluated by flow cytometry. (D,E) Siglec spacer CAR T
cells were cocultured with Raji or HEK293T cells for 5 h at a ratio of 1:1 and T cell expression of CD107a (D) and intracellular TNF-α (E) were analyzed by flow
cytometry. (F) The frequency of TIM3, LAG3, and PD1 triple positive CAR T cells was analyzed after 24 h co-culture at a 1:2 ratio of CAR T cells to Raji or HEK293T
cells by flow cytometry. CAR T cells alone were also cultured in order to exclude unspecific activation. n = 3. Error bars, mean ± SD. ns > 0.05, **p < 0.01, and ****p
< 0.0001 [one-way ANOVA, CAR T + Raji compared to Untreated (UnTd)].
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TSPAN8 has two extracellular loops extending from the
membrane that span 24 and 96 amino acids, respectively,
the larger having two interconnecting disulfide bonds. Thus,
the whole protein is very membrane proximal. On the
other hand, CD66c is a glycophosphatidylinositol anchored
protein and consists of two C2-set domains and one V-
set domain. In consequence it extends further into the
extracellular space compared to TSPAN8. In addition, the
epitope of the aCD66c scFv is localized on the outer N
terminal V-set domain. In summary, TSPAN8 can be considered
a membrane proximal target, while CD66c is a membrane
distal target.
We exchanged the Leu16 scFv from our CD20_hl_Sig4 CAR
with the CD66c and TSPAN8 specific scFvs that were previously
identified (Figure 5A) (Schäfer et al. manuscript under revision).
Additionally, we incorporated in our experiments CD66c
and TSPAN8 specific CD8α spacer CARs and a TSPAN8
specific IgG4 CH2-CH3 spacer CAR, which contained a
4/2 NQ mutation in the CH2 domain as well as a S→P
substitution which has been reported to reduce FcR binding
also in vivo (25), which was not the case for our IgG1
construct (25).
CD66c+/TSPAN8+ AsPC1 PDAC cells that were additionally
modified to express GFP and luciferase were co-cultivated with
CAR T cells specific for CD66c and TSPAN8 at an E:T ratio of
2:1 and analyzed using a fluorescent live cell analysis system.
We assessed cytotoxicity as a decrease in green fluorescence
surface area normalized to 2 h after co-inoculation. After 48 h,
a supernatant sample was taken for cytokine quantitation while
activation markers were measured at the end of the experiment
(132 h).
Both, the CD66c_lh_Siglec-4 CAR T cells, as well as the
untransduced control T cells showed no specific killing of target
cells, while the CD66c_lh_CD8 CAR showed a specific endpoint
killing of 42%, (Figure 5B). On the other hand, when targeting
the membrane proximal TSPAN8, the Siglec-4 spacer CAR T
cells showed a similar killing to that of the TSPAN8_hl_CD8α
CAR T cells approaching 60% endpoint killing. In contrast, CAR
T cells modified with a TSPAN8 CAR with the alternative long
IgG4 CH2-CH3 spacer exhibited only 40% killing at the end of
the experiment, showing the weakest cytotoxicity of all tested
TSPAN8 CAR T cells. The CD66c_lh_Sig4 CAR T cells, which
showed no cytotoxicity, also expressed no activation markers
(Figure 5C). The strongest upregulation of activation markers
4-1BB, LAG3 and PD-1 was observed in TSPAN8_hl_CD8α
CAR T cells. Interestingly, the TSPAN8 specific Siglec-4 CAR
T cells displayed a lower expression of activation markers, even
though the cytotoxicity equalled that of the CD8α spacer CAR
T cells. This difference between the CD8α and the Siglec-4
spacer CAR T cells was even more striking at the cytokine
level (Figure 5D). The TSPAN8_hl_CD8 CAR T cells released
markedly higher levels of cytokines than the other CAR T
cells. The TSPAN8_hl_Sig4 CAR T cells secreted cytokines at
levels more similar to CD66c_lh_CD8 and TSPAN8_hl_IgG4
CAR T cells, which was very surprising, with regard to
the same observed cytotoxicity as the TSPAN8 CD8α CAR
T cells.
The Siglec-4 Spacer Is Highly Efficacious
in an in vivo PDAC Model
Finally, we investigated the functionality of the three TSPAN8
specific CAR constructs in vivo in a pre-clinical PDAC tumor
model. 1 × 106 AsPC1 eGFP+/Luc+ cells were injected
subcutaneously in NSGmice. Tumor growth was measured non-
invasively by BLI imaging and furthermore assessed by physical
caliper measurement. When the first tumors reached a diameter
of 25 mm², treatment groups were randomized according to
the BLI signal and tumor size, and treatment was started by
i.v. injection of 5 × 106 CAR T or untransduced Mock T cells
(Figure 6A). Untransduced T cells did not display a therapeutic
benefit over the untreated group (Figure 6B). All mice from
these two groups had to be sacrificed before the end of the
experiment as tumor ulcerations began to become established.
The therapeutic effect for the CD8α and Siglec-4 CARs became
apparent in BLI measurements from day 6 onwards. The tumor
burden within the groups treated with the CD8α and Siglec-4
spacer CARs decreased in a comparable manner and reached
baseline by the end of the experiment 29 days after T cell
injection. At the same time, tumor growth was controlled by
the IgG4 CH2-CH3 spacer group, but there was no tumor
clearance as seen with the other groups. Persistence of CAR T
cells could be demonstrated in the spleens of all CAR T cell
treated groups with the highest amounts found in the CD8α
spacer CAR and Siglec-4 spacer CAR groups (Figure 6C). A
markedly lower amount of CAR T cells could be recovered from
the IgG4 spacer CAR group. Interestingly, when the phenotype
of the human T cells was examined the proportion of TCM was
twice as high in CD4 and CD8 CAR T cells of the Siglec-4
spacer CAR group as compared to the CD8α spacer CAR T cells
(Figure 6D).
DISCUSSION
Despite the largely empirical design of CARs based on the
functional principles of an antibody and the T cell receptor
(TCR), CAR T cell therapies have demonstrated remarkable
efficacy in the hematological tumor setting. Although a
direct comparison of results across CAR T cell-based clinical
trials is difficult due to the various differences in protocols,
target antigens, co-stimulatory signaling, treatment regimen,
patient groups and disease burden, the rough trend can
be observed that those receptors that incorporate a CD8α
or CD28 spacer region in their architecture display better
therapeutical efficacy than those that utilize IgG-based Fc
domains (1–7, 28–31). Non-clinical studies investigating
this effect suggest that the inferiority of IgG spacers is
due to the engagement with FcγR-expressing myeloid
cells (23) resulting in off-target activation of both gene-
modified T cells and the respective FcγR+ cells. In parallel,
additional work has been demonstrating that the exemplary
performance of CD8α or CD28 spacer CARs is partially also
attributed to the epitope location on the targeted antigen
CD19 and a number of studies have affirmed the postulate
that membrane-proximal epitopes are best targeted by
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FIGURE 5 | In vitro comparison of T cells transduced with TSPAN8 and CD66c CAR constructs, incorporating different spacer domains. (A) Structure of the TSPAN8
and CD66c CAR constructs with the Siglec spacers and extracellular domain comparison of the CAR constructs and target molecules. (B) Cytolytic kinetics and
specific endpoint killing of AsPC1 target cells incubated with CAR T cells and Mock T cells from three different donors in effector to target ratios of 2:1. n = 6. (C)
Frequency of 4-1BB, LAG3 and PD1 positive CAR T cells was analyzed at the end of the cytolytic evaluation with AsPC1 cells by flow cytometry. (D) GM-CSF, IFN-γ,
IL-2, IL-6, and TNF-α production after 24 h of co-culture of TSPAN8 or CD66c CAR T cells with AsPC1 cells from one donor assessed by flow cytometry. n = 2. Data
from (B–D) were taken from the same experiment. Shown is the mean ± SD. ns > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 [one-way ANOVA,
multiple comparisons].
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FIGURE 6 | The TSPAN8 specific Siglec-4 spacer CAR T cells exhibit the same anti-tumor efficacy as the CD8α spacer CAR T cells, while retaining a more
memory-like phenotype. (A) Overview of the study workflow. (B) Tumor burden and change in tumor size over time after TSPAN8 CAR T cell infusion. Untreated and
Mock T cell treated animals served as controls, T cells from one donor were used. IgG4: n = 5; Sig4 and CD8α: n = 4. PSM p < 0.05 (green) [one-way ANOVA,
multiple comparisons]. (C) Total number of CAR positive T cells recovered from spleens of TSPAN8 CAR-treated animals at the end of the experiment calculated after
flow cytometric analysis. IgG4: n = 5; Sig4 and CD8α: n = 4. (D) CD4 and CD8 CAR+ T cell phenotypes in the spleens of TSPAN8 CAR-treated animals analyzed at
the end of the experiment by flow cytometry. n = 4.
long spacer modules while membrane-distal epitopes are
effectively recognized by CARs incorporating short spacer
elements (18–22, 45).
In light of these developments, we identified a shortage
of functional CAR spacer modules for membrane-proximal
epitopes. Taking advantage of the well-described CD20 antigen
and the membrane-proximal binding epitope of Leu16-derived
anti-CD20 scFv (42), we sought to characterize the properties
of CD8α- vs. IgG-based spacer CARs against CD20 in vivo. To
avoid unintended cross-activation of CAR- and FcγR-expressing
cells in the context of the IgG spacer, the amino acid sequence
for IgG1-FcγR interactions in the IgG1-CH2 extracellular
domain of the CAR was replaced by the corresponding IgG2
amino acids as described previously (23). However, contrary
to reports describing increased anti-tumor activity and CAR
T cell persistence following modifications in the IgG4 spacer
to abrogate FcγR-binding in the CAR spacer domain (25, 27),
we did not observe any in vivo therapeutic efficacy of IgG1
CAR T cells after similar modifications in our study. More
specifically, the lack of efficacy was accompanied with an
inefficient persistence of the gene-modified T cells. These results
were in stark contrast to the functional capacity of the CD8αCAR
T cells which – according to current understanding – display
a less favorable receptor architecture due to the short spacer
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region. Although it is reasonable to conclude that the introduced
mutations into the IgG spacer domain may not entirely abrogate
FcγR binding, it cannot be ruled out that additional mechanisms
are in play that sacrifice the therapeutic efficacy. For example,
it has already been described that murine scFvs and other non-
self gene products can elicit HLA-restricted T cell-mediated
immune responses (3, 46, 47). Thus, the possibility exists that the
introducedmutations into the Fc region can create immunogenic
peptides by the T cell’s antigen processing machinery which
are then presented on the T cell’s HLA and render the gene-
modified lymphocytes susceptible to TCR-triggered fratricidal
activity. Therefore, it is to be appreciated that the interplay of
CAR T cells with their cognate counterparts and the immune
system is complex and further work is required to understand
the full immunogenic potential of CAR molecules.
To exclude the possibility of potential immunological barriers
elicited by the spacer region, we switched our test system to
the IgG4 backbone which was previously described to show in
vivo performance (25, 27) and which has also shown successful
translation to the clinic (34). In addition, a new set of spacer
domains was designed based on the Siglec family whose members
are expressed throughout the immune system and display
evolutionary structural similarities to the constant region of
immunoglobulins, but lack the inherent ability to interact with
FcγRs (35, 36). To determine systematically the optimal spacer
length for the membrane-proximal CD20 epitope, five Siglec
spacer CAR variants were generated incorporating either one,
two or three Ig domains. Of note, different parent proteins
were selected, as different Siglec molecules encompass distinct
glycosylation patterns which are likely involved in modulating
the protein’s stability, flexibility, spatial architecture etc. and thus
may have different effects on the CAR molecule. Moreover, in
an attempt to maintain the original architecture of the molecule,
the domains closest to the plasma membrane were selected.
Consequently, the Siglec spacer regions within the otherwise
identical CAR framework encompassed either a 114 amino acid
(aa) Siglec-3, 119 aa Siglec-7, 127 aa Siglec-8, 203 aa Siglec-7, and
280 aa Siglec-4 spacer domain as opposed to the control 45 aa
CD8α spacer domain.
Subsequent expression profiling revealed that not all Siglec
spacer-based CARs were efficiently expressed on the T cell
surface. In particular, Siglec-7.1 and Siglec-3 spacer CARs showed
the lowest expression efficiency emphasizing the importance of
the spacer region not only on the receptor’s functionality but
also on its optimal expression. In fact, Patel and colleagues
have already described that the CAR spacer domain can affect
the receptor’s stability and modify its turnover rate (17). It
is plausible that the glycosylation patterns present in Siglec-
7.1 and Siglec-3 spacer CARs render the receptors less stable,
in this way increasing the turnover kinetics and a decreased
CAR detectability on the cell surface. Another potential reason
for the inefficient expression of the Siglec-3 spacer CAR may
lie in the C169S mutation which was introduced in order to
abrogate unspecific disulfide bond formation as C169 is involved
in an interdomain disulfide bond within the parent protein.
Moreover, it is possible that the Siglec-3 C2-set domain per-
se is instable when isolated from the membrane-distal V-set
domain. Although a splice variant of CD33 has been described,
which lacks the N-terminal domain (CD331E2), these reports
rely on mRNA analyses (48, 49). Protein-based detection using
antibodies remains controversial, as it is still not clear whether
a clone exists that can specifically recognize the Siglec-3 C2-
set domain (49, 50). Importantly, using lentiviral transduction
of His-tagged CD331E2, Laszlo and colleagues have shown that
the expression of the splice variant is also dependent on the cell
type (49). In this context, HEK293T exhibited highest transgene
expression while hematopoietic cells displayed only low level
expression of the truncated immune receptor which is in line with
our observations on the expression of the Siglec-3 spacer CAR
(Figures 4B,C).
In the next series of experiments, the three best expressed
Siglec spacer CAR candidates were analyzed for their ability
to induce T cell effector function upon antigen engagement.
Consistent with previous reports (17–19, 25, 26, 51), our study
provides evidence that the CAR spacer region can modulate the
effector function of transgenic T cells. Intriguingly, however,
we find that depending on the effector function analyzed, the
functional hierarchy may vary. In particular with regard to
cytotoxicity, no significant differences between the CD8α spacer
(45 aa in length, no Ig domain) and Siglec-4 spacer (280 aa
in length; three Ig domains) CAR can be observed while in
terms of cytokine secretion the CD8α spacer CAR displays a
significant dominance over other CAR constructs. Importantly,
in addition to the CD20 system, this observation was further
confirmed in the setting of another membrane-proximal antigen,
TSPAN8, indicating a common functional feature formembrane-
adjacent epitopes.
It has already been demonstrated in the TCR-context
that distinct thresholds exist for the cytolytic machinery, the
proliferative induction as well as the cytokine production system
(52–56) and emerging work suggests similar principles for
CAR-triggered T cells (26). The current study further supports
this finding and the data obtained indicate that the nature
of the spacer region can modulate the nature and degree of
effector function. An alternative strategy has been described
by Liu and colleagues (57) and Caruso and colleagues (58)
in two independent studies, in which they demonstrate the
ability of effector function fine-tuning through scFv affinity
modulation. The clinical impact of such modifications was
impressively demonstrated by Ghorashian and colleagues, who
reported a better overall therapeutic profile of CD19 CAR T
cell therapies in patients who received lower affinity CARs
compared to the commonly used FMC63-scFv-based CARs (59).
In particular, while the antileukemic activity was retained, the
CAR T cells displayed an enhanced proliferative capacity and
reduced severity of cytokine release syndrome (CRS). Though
this clearly reveals the effectiveness of such an approach, scFv
affinity modulation is a laborious undertaking and bears the
risk to result in unwanted modifications to the target specificity.
Therefore, fine tuning the chimeric receptor’s spacer region
provides a time-profitable option with a lower risk profile. More
importantly, it further allows to create a variety of receptors
with a range of signal transduction intensities independent of the
binding domain.
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Besides, based on the efficacy data obtained with the CD8α
spacer (45 aa) vs. Siglec-4 spacer (280 aa) CARs targeting CD20
and TSPAN8, we find that the receptors’ cytotoxic efficacy is
not dominated by the spatial constraints of the CAR and its
target epitope. This is significant as previous studies reporting
such a trend were performed primarily in the context of IgG-
derived sequences (25, 26, 51) and have not been compared
extensively to spacers derived from other parental proteins.
Thus, our work demonstrates that not only structural and
spatial elements in CAR T cell:target cell interaction influence a
receptor’s bioactivity, but also additional factors are in play that
are not entirely understood or fully considered yet. It is likely
that e.g., CAR flexibility/rigidity and surface stability may have
a greater relevance than previously assumed. For instance, Patel
and colleagues have shown that the spacer domain can diminish
a CAR’s functionality by increasing its turnover rate (17). Thus,
it is important to take into consideration that Ig domains as they
are present in IgG and Siglec spacer domains display a distinct
structural folding while the CD8α spacer is derived from a stalk
connecting an Ig-like domain with the membrane. Attempts to
resolve the structure of the CD8α hinge domain were of limited
success so far, indicating the relative flexibility of this region
(60). The Siglec-4 or the IgG spacers are missing this flexibility
and in this way reduce targetable epitopes to the ones located in
membrane proximity.
Another important aspect to be taken into consideration is the
tendency of the CD8α stalk region to heterodimerize with CD8β,
the subunit that contains raft-localizing determinants (61). As
lipid rafts contain an accumulation of accessory molecules
decisive for signal transduction and the intracellular CD8β
domain has been described to promote association with the
two crucial players Lck and LAT (62), it is likely that – in
the context of cytotoxic T cells – the CD8α spacer region is
capable of attenuating the effector function threshold by fostering
interaction with downstream signaling molecules. These effects
are absent in IgG- and Siglec-based spacers, so that the overall
induction of T cell function is likely primarily guided by the
number of triggered CAR molecules (Figure S5).
In support of the in vitro data, the Siglec-4 spacer CAR
displayed a similar anti-tumor efficacy in vivo as the cognate
CD8α spacer CAR against TSPAN8 and both therapies were
superior to the IgG4-based spacer CAR treatment. Taking into
account the length of the spacer regions (CD8α: 45aa; Siglec-
4: 280 aa; IgG4: 228aa), we could not observe any obvious
correlation with CAR potency and rather identified an intrinsic
inferiority of the IgG4 spacer in vivo. However, in the context of
the TSPAN8 targeting, the modified IgG4 spacer CAR showed
a much better relative in vivo performance to the CD8α spacer
compared to the IgG1 spacer performance in the CD20 study.
Indeed, the modified IgG4 spacer (25) has now demonstrated
good efficacy in ongoing clinical studies (34) indicating that
other factors in CAR design such as the scFv binding domain,
transmembrane domain or the drug product formulation may
also play a role in in vivo function and T cell persistence.
Strikingly, however, while the cytotoxic activity was
comparable between the CD8α and Siglec-4 spacer CARs,
we observed a reduced secretion of pro-inflammatory cytokines
and an attenuated upregulation of activation/exhaustion markers
such as 4-1BB, LAG3, and PD1 in the Siglec-4 spacer CAR T
cells. Moreover, while the proliferative capacity of Siglec-4 CAR
T cells was slightly lower compared to CD8α spacer CAR T cells,
the Siglec-4 CAR-treated mice featured a trend toward a higher
fraction of TCM phenotype within the CAR T cell cohort which is
associated with better overall remission and decreased likelihood
of relapse in a clinical context.
It is currently widely established that CAR efficacy correlates
closely with the development and severity of CRS in the clinic, an
adverse event whose management has proven challenging in the
clinical setting. Although tocilizumab and glucocorticoids have
been described as effective intervention options, finding the right
timing for their application represents a big hurdle (1, 63). In fact,
too early intervention may jeopardize the therapeutic efficacy
and increase the risk of relapse, while too late intervention bears
the risk of CRS-induced multi-organ failure and irreversible
neurotoxicities resulting in a patient’s death (1, 3, 5, 7, 64–68).
Thus, a treatment modality that retains the cytotoxic ability of
currently approved CAR T cell therapies but attenuates the levels
of secreted cytokines may turn engineered T cells not only into
a reliable and effective, but also a safer platform. Moreover, a
concomitant increase of the memory phenotype in the CAR T
cell cohort of the patient holds promise to further increase the
therapeutic efficacy while reducing life-threatening side effects.
Although the phenotype of Siglec-4 CAR modified T cells
bodes well for future clinical application, what is the potential
toxicity profile of this novel spacer structure? The parent protein
Siglec-4, also known as myelin-associated glycoprotein (MAG),
has been reported to be exclusively produced by myelinating
glial cells such as oligodendrocytes in the central nervous system
(CNS; 1% of total protein mass) and Schwann cells in the
peripheral nervous system (PNS; 0.1% of total protein mass)
(69, 70). Its specific expression on the innermost layer of myelin
directly opposite to the axon surface supports its crucial role in
the stabilization of axon-myelin interactions, the regulation of
myelination, and the inhibition of axon regeneration after injury
(71–73). These effects have been first described to be mediated by
the N-terminal V-set domain of the receptor, as determined by
ligand specificity analyses, site-directed mutagenesis and analogy
to the crystal structure of Siglec-1 (74–77). In our evaluation
of homology studies, we found the protein sequence to be
the best conserved among the Siglecs and within mammalian
species. Indeed, the highest sequence homology was identified
to lie within the first two N-terminal domains of Siglec-4 (78).
Consequently, in order to abrogate these interactions, both N-
terminal domains were excluded from our CAR spacer design.
More recent studies, however, suggest that an alternative
binding domain exists that interacts with the Nogo receptor
1 and 2 (NgR1, NgR2), but not NgR3 (79–82). Deletion
analysis demonstrated that while the first three Ig-like C2-set
domains (amino acids 17-325) of Siglec-4 are involved in these
interactions, C2-set domains 3-5 (amino acids 234-506) as they
are present in our CAR architecture fail to associate with NgR1
or NgR2 (83) indicating that domains 1 and 2 are the major
interaction partners. Interestingly, both a soluble andmembrane-
bound receptor construct comprising the C2-set domains 3-5 of
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Siglec-4 (amino acids 234-506) are still able to inhibit neurite
outgrowth in the CNS, suggesting the existence of an as of
yet unidentified ligand partner (83, 84). This observation may
indicate the potential risk of unwanted interactions of the Siglec-
4 spacer-based CAR T cells with this unknown binding partner.
Although the CNS is an immune-privileged organ an intensive
infiltration by CAR T cells has been shown to occur as a result of
blood-brain-barrier (BBB) damage due to strong CRS. However,
as Siglec-4 spacer CAR T cells appear to produce lower levels of
cytokines, BBB disruption is expected to be mitigated, in this way
minimizing CNS accessibility for CAR T cells.
In support of this hypothesis, despite the high homology
between human and rodent Siglec-4 of 95% at the amino acid
level over the entire extracellular domain (85, 86), we did not
observe any toxicities in the mouse cohort receiving Siglec-4
spacer CAR therapy in our in vivo studies. Nevertheless, since
- to the best of our knowledge - human-mouse cross-reactivity
of Siglec-4 and its interaction partners has not been determined,
these data need to be handled with care and further analysis
is required to investigate the extent of potential side-effects of
Siglec-4 spacer-based CAR T cells.
In summary, this study introduces the new class of Siglec CAR
spacers, which structurally resemble IgG class spacers without
their FcγR binding features. The Siglec-4 spacer proved to be as
efficient as a conventional CD8α spacer in both in vitro and in
vivo CAR function, but exhibited advantageous traits in terms of
the T cell phenotype and CART cell cytokine release, whichmake
it an interesting candidate CAR structure to translate into future
clinical applications.
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